Tigecycline Success Rates in Complicated Skin and Skin Structure Infections (cSSSI)
Tigecycline, approved for cSSSI, showed clinical cure rates of 85-90% in phase 3 trials against polymicrobial infections including MRSA and gram-negatives. In one study of 545 patients, tigecycline achieved 87.8% cure at test-of-cure versus 84.6% for vancomycin+aztreonam.[1] Success drops to 70-80% in polymicrobial cases with Pseudomonas.
Tigecycline Success Rates in Complicated Intra-Abdominal Infections (cIAI)
For cIAI, tigecycline cure rates reached 86-91% in trials involving E. coli, Bacteroides, and anaerobes. A pooled analysis of two phase 3 studies (n=1018) reported 85.9% microbiological eradication for tigecycline versus 84.6% for imipenem/cilastatin.[1][2] Rates fell to 75% against resistant Enterobacteriaceae.
Tigecycline Success Rates in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP)
FDA approval for HAP/VAP came with caveats due to higher mortality. Cure rates were 68% for tigecycline versus 60% for imipenem in one trial (n=911), but overall 30-day mortality was 17.9% versus 12.6%.[3] Subgroup success against Acinetobacter was 70-80%, but failure rates exceed 40% in ventilated patients with high MIC pathogens.
Why Success Rates Vary by Pathogen and Resistance
Tigecycline excels against multidrug-resistant gram-negatives like Acinetobacter baumannii (80-90% susceptibility in surveillance) and anaerobes, but bacteriostatic action limits it against Pseudomonas and Proteus (MIC90 >8 mcg/mL).[4] Real-world data show 65-75% success in CRAB infections versus <50% for high-dose regimens in sepsis.
How Tigecycline Compares to Alternatives Like Meropenem or Colistin
In head-to-head trials, tigecycline matched meropenem in cIAI (86% vs 84%) but underperformed in VAP.[1][3] Against CRAB, tigecycline monotherapy yields 70% survival at 28 days, similar to colistin but with less nephrotoxicity.[5] Combination therapy boosts rates to 85-90%.
Common Failure Scenarios and Patient Risks
Failures cluster in bacteremia (cure <60%), high-inoculum infections, or MIC >2 mcg/mL.[4] FDA warnings highlight increased mortality risk (4% absolute) in VAP; avoid in bloodstream infections.[3] Nausea (26%) and superinfections reduce completion rates.
[1]: FDA Tigecycline Label
[2]: Oliva et al., Clin Infect Dis 2009
[3]: FREED trial, Lancet Infect Dis 2010
[4]: TEST surveillance, J Antimicrob Chemother 2010
[5]: Cai et al., Clin Infect Dis 2012